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Abstract
Background aims. Human dermal ABCB5-expressing mesenchymal stromal cells (ABCB5+ MSCs) represent a promising candi-
date for stem cellbased therapy of various currently uncurable diseases in several fields of regenerative medicine. We have devel-
oped and validated a method to isolate, from human skin samples, and expand ABCB5+ MSCs that meet the guideline criteria of
the International Society for Cellular Therapy.We are able to process these cells into a GoodManufacturing Practiceconforming,
MSC-based advanced-therapy medicinal product. Methods. To support the development of ABCB5+ MSCs for potential thera-
peutic topical, intramuscular and intravenous administration, we have tested our product in a series of Good Laboratory Practi-
cecompliant nonclinical in-vivo studies addressing all relevant aspects of biosafety, including potential long-term persistence and
proliferation, distribution to nontarget tissues, differentiation into undesired cell types, ectopic tissue formation, tumor formation
and local tissue reaction. Results. (i) Subcutaneous application of 1£ 107 ABCB5+ MSCs/animal and intravenous application of
2£ 106 ABCB5+MSCs/animal, respectively, to immunocompromisedmice did not result in safety-relevant biodistribution, persis-
tence or proliferation of the cells; (ii) three monthly subcutaneous injections of ABCB5+ MSCs at doses ranging from 1£ 105 to
1£ 107 cells/animal and three biweekly intravenous injections of 2£ 106 ABCB5+MSCs/animal, respectively, to immunocompro-
mised mice were nontoxic and revealed no tumorigenic potential; and (iii) intramuscular injection of 5£ 106 ABCB5+ MSCs/ani-
mal to immunocompromised mice was locally well tolerated. Discussion. The present preclinical in vivo data demonstrate the local
and systemic safety and tolerability of a novel advanced-therapy medicinal product based on human skin-derived ABCB5+MSCs.
KeyWords: stromal cells, stem cells, MSC, biodistribution, safety, ABCB5, GMP, tumorigenicity, toxicity, persistence
Introduction
Human dermal mesenchymal stromal cells (MSCs)
expressing the P-glycoprotein molecule ATP-bind-
ing cassette subfamily B member 5 (ABCB5) [1] rep-
resent an undifferentiated subpopulation of dermal
progenitor cells that fulfill the identity criteria for
MSCs proposed by the International Society for Cel-
lular Therapy [2]. In these physiological skin progen-
itor cells, ABCB5 functions as a determinant of the
membrane potential and as such regulates the
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propensity of the cell to remain undifferentiated or to
undergo differentiation [1]. ABCB5+ MSCs exert
immunomodulatory and anti-inflammatory effects
involving several pathways [35], making them a
promising novel therapeutic candidate for the treat-
ment of conditions associated with chronic inflam-
mation and tissue degeneration. Thus, ABCB5+
MSCs bear the potential to make a significant contri-
bution toward unmet needs of patients suffering
from various currently uncurable diseases. This pan-
orama prompted us to develop and validate a method
according to the requirements of Good Manufactur-
ing Practice (GMP) by which human dermal
ABCB5+ MSCs can be reliably isolated, expanded
on a large scale and manufactured as a homogenous
MSC population for future in-human use as an
advanced-therapy medicinal product (ATMP).
Even though the vast majority of clinical trials
conducted with MSCs derived from various sources
has not revealed any significant treatment-related
health concerns [68], stem cellbased products
basically may carry specific risks associated with
potential donor-to-recipient pathogen transmission
and/or undesired effects of the applied cells [9].
Thus, to ensure patient benefit and safety at its best,
in addition to rigorous, regulatory-compliant donor
screening and testing, a comprehensive set of GMP-
compliant quality and safety control measures are
carried out during the manufacturing process of our
ATMP, testing and securing identity, vitality, viabil-
ity and potency of the cells as well as purity and sta-
bility of the manufactured pharmaceutical product,
while precluding the presence of any conceivable bio-
burden and other adventitious agents. To further the
development of ABCB5+ MSCs as an ATMP for
potential topical, intramuscular and intravenous
administration, we have tested our final GMP-con-
form pharmaceutical product in a series of Good
Laboratory Practice (GLP)-compliant nonclinical in
vivo studies (listed in Table I) addressing all relevant
aspects of biosafety, including potential long-term
persistence and proliferation of the applied cells in
the host organism, distribution of the cells to nontar-
get tissues, differentiation into undesired cell types,
ectopic tissue formation, tumor formation, and local
tissue reaction.
Methods
Animals
NOD-scid (NOD/MrkBomTac-Prkdcscid) and NOG
(NOD-Shi-scid IL2Rgnull) mice were purchased from
Taconic (Ry, Denmark) and NSG (NOD scid
gamma; NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice from
Charles River (Saint-Germain-Nuelles France). At
initiation of treatment, the animals were 78 weeks
(biodistribution/persistence studies, toxicity/tumori-
genicity studies) or 910 weeks (local tolerance
studies) old. Mice were housed under special
hygienic conditions with 12 h/12 h light-dark cycle,
fed ad libitum with complete diet and had free access
to water. All animal experiments were performed by
specialized contract research organizations, meeting
the animal protection requirements defined in the
European regulations [10] and the applicable
national (German and UK) animal welfare legisla-
tions. All animal experimentation procedures had
been approved by the competent authorities: Regier-
ung Oberbayern, Germany (AZ 55.2-1-54-2532.2-
7-13, subcutaneous biodistribution/persistence
study; AZ 55.2-1-54-2532.2-13-12, subcutaneous
toxicity/tumorigenicity study); United Kingdom
Home Office, Animals in Science Regulation Unit
(PPL 70/08287, October 2014, intravenous biodis-
tribution/persistence study; PPL 80/02501, January
2012, intravenous toxicity/tumorigenicity study);
and Landesamt f€ur Umwelt, Gesundheit und Ver-
braucherschutz des Landes Brandenburg, Germany
(V3-2347-A-13-8-2011, 6 February 2012, local tol-
erance studies).
Isolation, production and potency testing of human
ABCB5+ MSCs
After informed written consent, human ABCB5+
MSCs were derived from skin samples obtained
from patients undergoing abdominoplasties or other
medical interventions providing leftover skin tissue.
Cell production took place in a clean-room facil-
ity complying with GMP grade AD regulations,
following a validated protocol. In brief, skin tissue
was freed from excess subcutaneous adipose tissue,
disinfected, washed, dissected into pieces and enzy-
matically digested. Cells were centrifuged and
expanded after adherence selection in stem
cellselecting growth media as unsegregated cell cul-
ture. ABCB5+ MSCs were isolated by antibody-cou-
pled magnetic bead sorting using a mouse anti-
human ABCB5 monoclonal antibody [1]. Purity of
the isolated cells was determined by flow cytometry;
a content of 90% ABCB5+ cells was set as a release
criterion, with the remaining up to 10% (mean:
3,8%) being ABCB5-negative MSCs that also meet
the International Society for Cellular Therapy guide-
line criteria. Corresponding to the main modes of
action of MSCs, that is (i) immunomodulation
(switch from pro-inflammatory M1 to anti-inflam-
matory M2 macrophages), (ii) secretion of bioactive
molecules (mediation of angiogenesis and neo-vascu-
larization) and (iii) trans-differentiation (into CD31-
expressing endothelial cells), the following validated
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assays were used for potency testing: (i) secretion of
interleukin-1 receptor antagonist in a co-culture with
M1-polarized macrophages (enzyme-linked immu-
noassay [ELISA] based screening assay), (ii) secre-
tion of VEGF when cultured under hypoxic
conditions (ELISA-based screening assay), and (iii)
tube formation assay in extracellular matrix for con-
struction and forming of vessels (trans-differentiation
assay, microscopic evaluation). Upon meeting the
release specifications, cells were cryo-preserved in
CryoStor CS10 freeze medium (BioLife Solutions,
Bothell, WA) containing 10% dimethyl sulfoxide
and stored in the gas phase of liquid nitrogen.
Reconstitution and injection of human ABCB5+ MSCs
ABCB5+ MSCs were thawed, washed and suspended
in HRG solution (Ringer’s lactate solution containing
2.5% human serum albumin and 0.4% glucose) at con-
centrations ranging from 5£ 105 to 5£ 107 cells/mL,
as required. The injection volume (200 mL) was drawn
up into a sterile single-use 500-mL or 1-mL syringe.
Immediately before injection, the syringes were gently
inverted 510 times to ensure homogenous suspension
of the cells. For injection, mice were isoflurane-anesthe-
tized. Subcutaneous injections (23-G needle) were
given at the right flank, intravenous injections (26-G
needle) into the left or right caudal vein, and
intramuscular injections (30-G needle) split over four
injection sites at the left thigh muscles after shaving the
left thigh with an electric clipper. Intravenous and intra-
muscular injections were given at a rate of 10 mL/5 s.
HeLa cells
HeLa cells (ATCC CCL-2) were cultured in Eagle’s
Minimum Essential Medium containing 10% fetal
bovine serum, 2 mmol/L glutamine, 1% nonessential
amino acids, 1 mmol/L sodium pyruvate, 100 U/mL
penicillin and 100 mg/mL streptomycin. Cells were pas-
saged at least twice. On the day of dosing, cells were
harvested using trypsinethylenediaminetetraacetic
acid solution, pelleted by centrifugation and then rinsed
once with phosphate-buffered saline (PBS) before
being resuspended in PBS at a concentration of
5£ 107 cells/mL (subcutaneous tumorigenicity study)
and 5.4£ 106 cells/mL (intravenous tumorigenicity
study), respectively. The injection volume (200 mL)
was drawn up into a sterile single-use 1-mL syringe and
given subcutaneously into the right flank.
Histopathology
After sacrifice of the animals, all organs and tissues
designated for histopathological assessment were dis-
sected and preserved in 10% neutral buffered formalin
Table I. Overview over the preclinical in vivo safety study program of ABCB5+ MSCs.
Mouse strain Number of animals Treatment Route and time of application Observation period
Biodistribution and persistence studies
NOD-scid 40 (20 M, 20 F) 1£ 107 ABCB5+MSCs/animal SC, day 1 1 week (n = 10)
3 months (n = 10)
4 months (n = 10)
Vehicle 4 months (n = 10)
NSG 40 (20 M, 20 F) 2£ 106 ABCB5+MSCs/animal IV, day 1 1 week (n = 10)
4 weeks (n = 10)
13 weeks (n = 10)
Vehicle 13 weeks (n = 10)
Repeated-dose toxicity and tumorigenicity studies
NOD-scid 110 (55 M, 55 F) 1£ 105 ABCB5+MSCs/animal (n = 20) SC, days 1, 29, 57 1216 weeks
1£ 106 ABCB5+MSCs/animal (n = 20) 12 weeks
1£ 107 ABCB5+MSCs/animal (n = 30) 12 weeks
Vehicle (n = 30) 1216 weeks
1£ 107 HeLa cells/animal (n = 10) SC, day 1 51 days
NSG 50 (25 M, 25 F) 2£ 106 ABCB5+MSCs/animal (n = 20) IV, days 1, 15, 29 13 weeks
Vehicle (n = 20)
1.08£ 106 HeLa cells/animal (n = 10) SC, day 1
Local tolerance studies
NOG 16 males 5£ 106 ABCB5+MSCs/animal (n = 8) IM, day 1 7 days
Vehicle (n = 8)
NOG 24 males 5£ 106 ABCB5+MSCs/animal (n = 8) IM, day 1 28 days
Vehicle (n = 8)
PBS (n = 8)
F, female; IM, intramuscular; IV, intravenous; M, male; SC, subcutaneous.
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solution containing approximately 4% formaldehyde
(testes and eyes: modified Davidson’s fixative). The
samples were trimmed, processed, embedded in paraf-
fin wax, cut to an approximate thickness of 25 mm,
stained with hematoxylin and eosin (H&E), and
inspected by conventional light microscopy.
Detection of human-specific DNA
In the biodistribution and persistence studies, the
following tissues and organs were collected for detec-
tion of human-specific genomic DNA using quanti-
tative polymerase chain reaction (qPCR) according
to a validated protocol: blood, injection depot (only
after subcutaneous administration and only from
animals sacrificed 1 week after cell administration),
skin/subcutis and skeletal muscle at the injection site,
lymph node draining the injection site, contralateral
lymph node, liver, spleen, lungs, brain, femur bone,
femur bone marrow, kidneys, thymus, thyroid/para-
thyroid gland and ovaries or testes. In the subcutane-
ous repeated-dose toxicity study, enlarged organs
considered to result from spontaneous lymphoma
development were collected for human-specific
genomic DNA detection.
In the subcutaneous biodistribution/persistence
and toxicity/tumorgenicity studies, soft tissues (mus-
cle, lymph nodes, liver, spleen, lung, brain, kidney,
thymus, thyroid/parathyroid gland and ovaries or tes-
tes) were taken up in lysis/binding buffer (Roche,
Mannheim, Germany) and ground with a micro-
pestle. As positive controls, two additional aliquots
of liver tissue from one vehicle-treated animal were
prepared, and 10 000 human ABCB5+ MSCs in 50
mL saline were added for spiking. Hard tissues (skin,
bones) were taken up in lysis/binding buffer (Roche)
into homogenization tubes containing ceramic beads
(Precellys Ceramic kit 2.8 mm; VWR, Darmstadt,
Germany) and disrupted in a MagNA Lyser Instru-
ment (Roche) for 2£ 25 s at 6000 rpm with 90 s
cooling between the two cycles. Nucleic acid extrac-
tion from tissue homogenates and blood was per-
formed with an automated nucleic acid extraction
system (MagnaPure LC, Roche) using the Total
Nucleic Acid Isolation kit. For detection of human
DNA sequences, forward primer cr17_1a, reverse
primer cr17_4b and the FAM-TAMRA-labeled
probe TMsatex were used. For detection of mouse
DNA sequences, forward primer PTGER2hmf,
reverse primer PTGER2r and the VIC-NONE-
labeled MGB probe MOUQ01 were used. For
sequences, see supplementary Table I. Cycle 40 was
set as detection cutoff.
In the intravenous biodistribution and persis-
tence study, tissues were taken up in lysis buffer T1
and proteinase K (NucleoSpin 96 Tissue kit,
Macherey-Nagel, D€uren, Germany) into homogeni-
zation tubes containing ceramic beads (for soft tis-
sues) or steel beads (for bone tissue) and
homogenized using the Precellys Evolution homoge-
nizer (Bertin Technologies, Frankfurt, Germany) at
6000 rpm for least two cycles (20 s each) at room
temperature with at least 30 s pause between two
cycles. When further cycles were needed, samples
were cooled in between. Nucleic acid extraction
from tissue homogenates and blood was performed
using NucleoSpin 96 Tissue kit (Macherey-Nagel).
For detection of human DNA sequences, forward
primer ACC-25, reverse primer ACC-26 and FAM-
labeled probe ACC-27 (Microsynth, Balgach, Swit-
zerland) were used. For detection of mouse DNA
sequences, forward primer ACC-28, reverse primer
ACC-29 and TAMRA-labeled probe ACC-30
(Microsynth) were used. For sequences, see supple-
mentary Table I. The lower limit of quantification
was 125 cells.
Immunohistochemistry
AMA and Ki67 staining
Formalin-fixed, paraffin-embedded lung and skin
tissue samples were sectioned at three levels approxi-
mately 100 mm apart. At each level three sequential
4- to 5-mm-thick sections were taken and stained
with H&E, AMA antibody (ab92824, Abcam, Cam-
bridge, United Kingdom, 2 mg/mL; secondary anti-
body: biotinylated rabbit anti-mouse, E0413, Dako,
Glostrup, Denmark) and anti-Ki67 antibody
(ab16667, Abcam, dilution 1:200; secondary anti-
body: biotinylated goat anti-rabbit, E0423, Dako),
respectively, according to validated protocols. Sec-
tions designated for H&E and AMA staining were
stained and examined first. Only if the AMA staining
was positive, the corresponding third slide was then
stained with the anti-Ki67 antibody.
b2-Microglobulin staining
Staining of 4-mm sections of paraffin-embedded
thigh muscle specimens was performed using rabbit
anti-b2-microglobulin (polyclonal, immunoglobu-
lin G, Abcam; dilution 1:200) incubated for 60 min
at room temperature. Staining was carried out with
Leica Bond III fully automated staining system
using the horseradish peroxidase (HRP)-linker anti-
body conjugate system Bond Polymer Refine Detec-
tion kit as secondary reagent (Leica Biosystems,
Wetzlar, Germany).
Vimentin staining
Staining of 4-mm sections of paraffin-embedded thigh
muscle specimens was performed out using rabbit
anti-vimentin (ab137321, polyclonal immunoglobulin
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G, Abcam; dilution 1:1000) incubated for 60 min at
room temperature. Staining was carried out with
Leica Bond III fully automated staining system using
the HRP-linker antibody conjugate system Bond
Polymer Refine Detection kit as secondary reagent
(Leica Biosystems).
Statistics
Data acquisition and analysis were carried out using
the integrated software system PDS ToxData 3.0
(Pathology Data Systems, Pratteln, Switzerland).
In the subcutaneous biodistribution and persis-
tence study, inferential statistics were based on the
results of a ShapiroWilk test. In the case of normal-
ity, homogeneity of medians was assessed by Levene
test and analysis of variance. In the case of non-
normality and non-homogeneity, a nonparametric
KruskalWallis test was performed. Multiple compar-
isons were carried out using a post hoc Dunn’s test.
In the intravenous biodistribution and persistence
study, cell concentrations as detected by qPCR were
statistically analyzed by non-paired one-way analysis of
variance followed by Tukey’s multiple comparison test.
In the subcutaneous repeated-dose toxicity and
tumorigenicity study, inferential statistics were per-
formed according to four different decision trees,
based on the results of a ShapiroWilk test, Kolmo-
gorovSmirnov test and Bartlett test, respectively,
followed by appropriate post hoc testing procedures.
In the intravenous repeated-dose toxicity and
tumorigenicity study, inferential statistics were based
on the results of a Bartlett test for variance homoge-
neity. If the Bartlett test was not significant at the 1%
level, a parametric analysis was performed. Groups
were compared using t-tests. If the Bartlett test was
still significant at the 1% level following both loga-
rithmic and square-root transformations, a nonpara-
metric analysis was performed. Groups were
compared using Wilcoxon rank sum tests.
In the local tolerance studies inferential statistics
were not performed due to the rather descriptive
character of these studies.
Results
Biodistribution and persistence of ABCB5+ MSCs after
single subcutaneous administration
Three groups of 10 (5 male, 5 female) NOD-scid
mice were subcutaneously injected with 1£ 107
ABCB5+ MSCs/animal. Mice were followed up for 1
week, 3 months and 4 months, respectively, then sac-
rificed and subjected to necropsy. As control, a
fourth group of 10 mice received vehicle without
cells and was followed up for 4 months.
Although no spontaneous deaths occurred, two
moribund animals, suffering from spontaneously
developed lymphoma, which is known to be a fre-
quent occurrence in NOD-scid mice [11], were
euthanized during the observation period (days 90
and 69, respectively). In general, clinical findings
noted during the observation period as well as mac-
roscopic pathological findings were either associated
with spontaneously developing lymphomas or related
to shaving, housing or cage mates. There were no
clinical or necropsy findings related to administration
of ABCB5+ MSCs noted in any of the animals.
In MSC-treated animals, human DNA sequences
were detectable by qPCR in all subcutaneous injec-
tion depots and two injection site-draining lymph
nodes after 1 week and in one skin sample after
3 months, but not in any other tissue and blood
examined. A further positive result in one brain sam-
ple after 1 week was considered accidental (probably
contamination-related), as it was observed only in
one of two aliquots tested. In vehicle-treated ani-
mals, human DNA sequences could not be detected
in either organ/tissue, whereas mouse DNA sequen-
ces were detectable in all tissues and at all time points
in MSC- and vehicle-treated animals, both of which
confirming the reliability of the method.
Biodistribution and persistence of ABCB5+ MSCs after
single intravenous administration
To investigate trafficking, homing, engraftment, dif-
ferentiation and persistence of human ABCB5+
MSCs after single intravenous administration, three
groups of ten (five male, five female) NSG mice were
intravenously injected with 2£ 106 ABCB5+ MSCs/
animal in 200 ml vehicle solution. After cell injection,
mice were followed up for 1, 4, and 13 weeks, respec-
tively, after which the mice were sacrificed. As con-
trol, a fourth group of 10 mice received vehicle
without cells and was followed up for 13 weeks. Dur-
ing these periods, no case of death and no treatment-
related effects on body weight and clinical signs
occurred.
In MSC-treated animals, human-origin cells, as
revealed by detection of human DNA sequences
using qPCR, were predominantly recorded in the
injection site tissues (skin and skeletal muscle) and in
the lungs (Table II), where human-origin cells were
detectable in individual animals up to the end of the
study (day 92). This points to a certain degree of per-
sistence of the administered MSCs in these tissues.
Maximum cell concentrations were measured in
individual injection-site tissue samples on day 8 and
in individual lung tissue samples on day 29, declining
thereafter. The mean cell concentration observed in
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the lungs was, however, not significantly increased in
day 29 compared with day 8 samples but was signifi-
cantly reduced in day 92 samples (Figure 1).
In the tissues beyond injection site and lungs,
human DNA was occasionally detected across the
various tissue types (except for reproductive organs
Table II. Concentration of human-origin cells in injection-site tissues and lungs of NSG mice intravenously injected with 2£ 106 ABCB5+
MSCs.
Cell concentration (cells/mg tissue)
Injection site tissues
Time after cell application Sex Animal number Skin Skeletal muscle Lung
Day 8 (1 week) M 6 8  36
7 162 Detected 
8 59 46 14
9 13  11
10   
F 36 Detected 200 12
37 Detected 129 7
38 16 Detected 31
39 39  19
50 Detected  10
Day 29 (4 weeks) M 11   15
12 21 Detected 15
13 18  12
14 Detected Detected 30
15 7 Detected 10
F 40   
41 33 19 44
42 18 24 7
43 Detected 15 35
51   32
Day 92 (13 weeks) M 16 17  
17  57 7
18   6
19 31 46 
20 11 35 9
F 45   
46 Detected  
47 8  
48 13 17 7
49 8 18 
Animals were sacrificed at 1, 4 or 13 weeks after cell injection. Human-origin cells were determined by detection of human-specific DNA
using qPCR. Detected = value < lower limit of quantification but> 2.5£ blank; = undetected. F, female; M, male.
Figure 1. Concentration of human-origin cells as detected by qPCR in injection-site tissues (skin and skeletal muscle) and in the lung of
NSG mice at 8 (black bars), 29 (light gray bars) and 92 days (medium gray bars) after intravenous injection of 2£ 106 ABCB5+ MSCs.
Shown are means of 10 animals; error bars indicate SD; **P < 0.01, non-paired one-way analysis of variance followed by Tukey’s multiple
comparison test. A separate control group (not shown), comprising the mice injected with cell-free vehicle and sacrificed 92 days thereafter,
did not reveal any detectable human-origin cells except for muscle tissue of one animal, which was considered an artifact (see Results).
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and brain) in individual MSC-treated animals. How-
ever, quantifiable levels of human cells could only be
detected in one kidney (7 cells/mg) and one thymus
(151 cells/mg) sample taken on day 29, but not in
any other of totally 300 tissue and organ samples
beyond injection-site tissues and lungs of the 30
MSC-treated animals. Because these positive signals
were singular findings and no quantifiable cell con-
centrations were recorded in the same tissue types at
earlier or later time points, we consider these two
positive findings out of 300 samples as incidental,
likely resulting from accidental contamination with
human cells by the investigators during animal han-
dling and/or tissue sampling or preparation.
Unexpectedly, quantifiable human-origin cell
concentrations were detected in four individual sam-
ples from 4 out of 10 control animals taken on day
92 (skeletal muscle: 51 cells/mg; thyroids: 82 and
359 cells/mg, respectively; ovaries: 19 cells/mg).
However, all other 126 samples analyzed from con-
trol animals as well as all assay controls, that is blank
(not-spiked mouse matrix) and no-template control
(DNAse-free water) samples, tested negative for
human cells, which argues against a false-positive
background signal of the assay. Instead, given the
high sensitivity of our assay detecting as little as 125
cells in 200 mL tissue lysate or 100 mL blood and the
high contamination risk associated with qPCR tech-
niques, we deem these findings to have resulted from
contamination during sample processing at an inde-
terminate stage. Because such contamination poses a
certain risk to overestimate but in no way underesti-
mate the presence of human MSCs in the examined
tissues, we do not consider these findings to be detri-
mental to the validity or integrity of our data in terms
of safety evaluation.
Immunohistochemical staining of injection sites
and lungs of the MSC-treated animals with a
human-specific antimitochondrial antibody (AMA)
and, in case of AMA positivity, with an antibody
against the proliferation marker Ki67 was performed
on lung tissue samples from all 30 animals and skin
samples from 25 animals (for 5 of 10 animals at the
13-week time point, there was no skin tissue avail-
able). Positive AMA staining was observed in the
subcutaneous injection-site tissue of one animal and
within a thrombus in a lung vessel of another animal,
both sacrificed at 1 week after MSC application.
Cells staining positively for AMA were spindloid-
shaped. Only in the lung thrombus was positive
staining observed also for Ki67, with the majority of
positively staining cells staining positively only for
either AMA or Ki67. Most Ki67+ cells appeared as
clumsy cells with oval-shaped nuclei, thus morpho-
logically being clearly different from the AM+
(human-origin) cells. Such host-origin Ki67+ cells
would be expected within a thrombus due to active
reorganization of the thrombus. Nevertheless, in
some areas of the thrombus, positive staining for
Ki67 and AMA was seen in close association, and as
such, it could not be completely ruled out that some
cells could have stained positive for both. However,
all cells staining positive for AMA were scattered
throughout the thrombus and did not show any evi-
dence of clustering together to form a mass. No posi-
tive staining for Ki67 was seen at the injection site,
indicating that the subcutaneously detected human
cells were not actively proliferating. No AMA+ cells
were observed at later time points (4 and 13 weeks
after MSC application, respectively).
Combined study on subcutaneous repeated-dose toxicity
and tumorigenicity
To assess the potential toxicity of human ABCB5+
MSCs, male and female NOD-scid mice were ran-
domly allocated to receive three doses of 1£ 105
(n = 20), 1£ 106 (n = 20) or 1£ 107 (n = 30)
ABCB5+ MSCs/animal or vehicle without cells (neg-
ative control, n = 30), injected subcutaneously on
days 1, 29 and 57. In addition, the tumorigenic
potential of human ABCB5+ MSCs was assessed in
the high-dose group treated with 1£ 107 cells/animal
(as recommended by the World Health Organization
[12]). A fifth group of mice receiving a single injec-
tion of 1£ 107 HeLa cells on day 1 (n = 10) served
as positive control. Full necropsy and subsequent
histopathological evaluation were performed after 12
weeks of daily observation, except for HeLa
celltreated mice, which were euthanized for animal
welfare reasons on day 51. The vehicle and the high-
dose group both included additional five male and
five female mice undergoing an additional 4-week
recovery period (necropsy and subsequent histopath-
ological evaluation after 16 weeks).
With regard to the investigated toxicology parame-
ters (i.e., mortality, clinical signs, body weight devel-
opment, food consumption, ophthalmologic
examination, urinalysis, hematology, blood chemistry
and coagulation, organ weights, macro-pathological
and histopathological findings), the study did not
reveal any relevant adverse effects related to ABCB5+
MSCs (for details, see supplementary Tables IIIV).
The predominant histopathological findings were
systemic lymphoblastic neoplasms, with incidences
ranging between 5% in the medium-dose MSC
group and 17% in the vehicle group. These neo-
plasms are known to spontaneously develop in
NOD-scid mice [11] and were clearly judged not
related to the application of ABCB5+ MSCs
(see Discussion). In the positive-control (HeLa
celltreated) group, subcutaneous nodules were
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palpated in all (10 of 10) animals at the injection site
from day 6 (males) and day 8 (females) on. Due to
the progressive tumor growth for more than 2 weeks,
these animals were euthanized on day 51.
Combined study on intravenous repeated-dose toxicity
and tumorigenicity
The potential toxicity and tumorigenicity of human
ABCB5+ MSCs after intravenous administration
was assessed in male and female NSG mice ran-
domly allocated to receive three intravenous injec-
tions of 2£ 106 ABCB5+ MSCs/animal (n = 20) or
vehicle without cells (negative control, n = 20) on
day 1, 15 and 29. As positive control (i.e., to validate
the used mouse strain as being susceptible to tumor
formation), 10 mice received 1.08£ 106 HeLa cells
injected subcutaneously on day 1. Albeit this dose
level was, due to technical reasons, lower than the
level recommended by the World Health Organiza-
tion (1£ 107 cells/mouse [12]), it was considered
sufficient in the mouse strain used because all these
mice developed tumors (discussed subsequently).
During a 13-week observation period, mortality,
clinical condition, palpable masses, body weight
development, food consumption, ophthalmologic
findings and hematological and blood chemistry
parameters (both in the peripheral blood sampled
from the retro-orbital sinus under isoflurane anesthe-
sia before sacrifice) were recorded. Thereafter, the
mice were sacrificed and subjected to full necropsy,
including organ weight measurements and macro-
and histopathological examination.
In most cases either no significant changes
between vehicle- and MSC-treated animals were
observed, or the observed findings were judged unre-
lated to the treatment with ABCB5+ MSCs, based
on incidence and distribution. The deaths of two
MSC-treated mice (day 1 and day 15, respectively)
were considered related to the injection procedure.
Body and organ weight development were not basi-
cally altered in the MSC-treated group (Table III).
Minor differences between vehicle- and MSC-
treated animals were seen for some hematology and
clinical chemistry parameters (Table IV). In all (10/
10) HeLa cell-treated mice, dorsocranial and/or dor-
socaudal masses were palpable on the right side of
the body in the region of the injection site. Three
mice developed also dorsocranial/dorsocaudal
masses on the left side of the body. In contrast, no
palpable masses were detectable on vehicle- or
MSC-treated animals, and neither macro-pathologi-
cal nor histopathological examination revealed evi-
dence of tumor forming in these groups (Table V).
To complement and expand the findings of the ear-
lier-reported (single-dose) intravenous biodistribution
and persistence study to the repeated-dose setting, lungs
and injection-site tissues of all MSC-treated animals
were stained with human-specific AMA and an anti-
body against the proliferation marker Ki67 to evaluate
the presence and proliferation status of the intravenously
administered ABCB5+ MSCs. The lungs of four vehi-
cle-treated animals served as negative control, whereas
injection-site tissue of a HeLa celltreated animal was
used for assay validation.
In lung tissue, positive AMA staining was seen in
of 7 of the 20 animals treated with human ABCB5+
MSCs, indicating the presence of cells of human ori-
gin in the lungs. Staining was exceptionally rare (fre-
quently amounting to no more than 12 cells per
tissue section), and the positively staining cells were
situated within the walls of the alveoli or, occasionally,
free within the alveoli (Figure 2). In one animal, a
cluster of positively staining cells was seen within the
lumen of a lung vessel. This cell cluster was also visi-
ble on the corresponding H&E-stained section,
although the cell type could not be identified. This
appeared to be a thrombus that had detached from
the vessel wall during histological processing as a
small section of vessel wall adhered to these cells. At
the injection sites, there was no positive AMA staining
Table III. Body weight (alive) and selected organ weights of NSG
mice following three intravenous injections of 2£ 106 ABCB5+
MSCs/animal or vehicle without cells on day 1, 15 and 29.
Vehicle 2£ 106 MSCs/animal
Males
Body weight (alive), g n = 10 n = 10
Baseline 27.9 (1.34) 27.9 (0.94)
13 weeks 34.4 (1.52) 32.7 (0.69)*
Organ weight, g n = 10 n = 9
Brain 0.4783 (0.0168) 0.4853 (0.0120)
Heart 0.1800 (0.0132) 0.1684 (0.0069)
Kidneys 0.5599 (0.0572) 0.5079 (0.0269)
Liver 1.9112 (0.1416) 1.6879 (0.0532)**
Spleen 0.0259 (0.0062) 0.0222 (0.0028)
Testes 0.2059 (0.0122) 0.2047 (0.0083)
Thymus 0.2059 (0.0122) 0.2047 (0.0083)
Females
Body weight, g n = 10 n = 10
Baseline 21.8 (1.29) 22.1 (1.59)
13 weeks 26.6 (1.23) 26.9 (2.13)
Organ weight, g n = 10 n = 10
Brain 0.4931 (0.0125) 0.4879 (0.0143)
Heart 0.1395 (0.0111) 0.1373 (0.0108)
Kidneys 0.3076 (0.0204) 0.3112 (0.0185)
Liver 1.3087 (0.0888) 1.2165 (0.1176)*
Ovaries 0.0212 (0.0043) 0.0210 (0.0044)
Spleen 0.0249 (0.0037) 0.0243 (0.0033)
Thymus 0.0086 (0.0028) 0.0069 (0.0030)
Animals were followed up for 13 weeks. Values are means (SD).
*P < 0.05, **P < 0.01 versus vehicle group, t-test on log-trans-
formed data (body weight) or after adjustment for body weight
(organ weights).
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seen in any animal. K-67 staining revealed no positive
signals that corresponded to the AMA-positive cells in
any tissue section from any of the animals examined.
Seven-day local tolerance of intramuscularly injected
ABCB5+ MSCs
To evaluate potential local muscular side effects,
male NOG mice were intramuscularly injected with
5£ 106 ABCB5+ MSCs/animal in 200 mL vehicle
(n = 8) or with 200 mL vehicle without cells (n = 8).
One animal in the control group died during applica-
tion of the vehicle, probably due to intolerance to
anesthesia. Mice were followed up for 7 days, during
which no effects of the treatment on general condi-
tion including body weight development and food
consumption became apparent.
At necropsy all injection muscles appeared mac-
roscopically inconspicuous. Histopathological exam-
ination revealed minor degenerative/regenerative
myofiber reactions at the injection sites of vehicle-
treated animals (Figure 3, left). Myofiber degenera-
tion was manifest in form of focal, small, basophilic
fibers. Regenerative large myoblasts were present.
Table IV. Selected hematology and clinical chemistry parameters
of NSG mice after three intravenous injections of 2£ 106 ABCB5+
MSCs/animal or vehicle without cells on day 1, 15 and 29.
Vehicle
2£ 106
MSCs/animal
Males n = 10 n = 9
Hematology
Hematocrit, L/L 0.459 (0.0257) 0.476 (0.0144)
Hemoglobin, g/dL 12.6 (0.63) 13.0 (0.27)
White blood cells,£ 109/L 0.81 (0.207) 1.10 (0.574)
Neutrophils,£ 109/L 0.53 (0.153) 0.65 (0.233)
Lymphocytes,£ 109/L 0.22 (0.126) 0.33 (0.357)
Monocytes,£ 109/L 0.04 (0.023) 0.09 (0.039)**
Eosinophils,£ 109/L 0.02 (0.010) 0.03 (0.011)
Clinical chemistry
AST, U/L 45 (9.7) 43 (7.9)
ALP, U/L 46 (3.1) 45 (2.8)
Urea, mmol/L 8.56 (0.741) 7.72 (0.433)*
Cholesterol, mmol/L 2.63 (0.127) 2.38 (0.240)*
Triglycerides, mmol/L 1.02 (0.273) 0.61 (0.194)**
Glucose, mmol/L 14.09 (1.271) 15.82 (2.533)
Na+, mmol/L 152 (1.2) 152 (2.2)
K+, mmol/L 4.3 (0.41) 4.4 (0.32)
Ca2+, mmol/L 2.39 (0.045) 2.34 (0.072)*
Albumin, g/L 31 (1.1) 29 (0.8)**
Total protein, g/L 49 (1.3) 46 (1.5)**
Females n = 10 n = 10
Hematology
Hematocrit, l/L 0.490 (0.0096) 0.478 (0.0154)*
Hemoglobin, g/dL 13.6 (0.38) 13.5 (0.43)
White blood cells,£ 109/L 0.93 (0.256) 0.80 (0.256)
Neutrophils,£ 109/L 0.62 (0.153) 0.55 (0.164)
Lymphocytes,£ 109/L 0.23 (0.140) 0.18 (0.137)
Monocytes,£ 109/L 0.06 (0.038) 0.05 (0.016)
Eosinophils,£ 109/L 0.02 (0.013) 0.02 (0.010)
Clinical chemistry
AST, U/L 48 (10.8) 43 (8.3)
ALP, U/L 77 (8.1) 73 (6.0)
Urea, mmol/L 7.37 (0.619) 6.83 (0.483)
Cholesterol, mmol/L 1.94 (0.143) 1.81 (0.151)
Triglycerides, mmol/L 0.63 (0.271) 0.42 (0.220)
Glucose 15.09 (1.147) 11.93 (1.829)**
Na+, mmol/L 151 (1.3) 151 (2.9)**
K+, mmol/L 3.7 (0.30) 4.0 (0.29)*
Ca2+, mmol/L 2.39 (0.046) 2.34 (0.055)*
Albumin, g/L 31 (0.6) 31 (1.1)
Total protein, g/L 46 (1.2) 46 (1.3)
Animals were followed up for 13 weeks. Values are means (SD);
*p<0.05, **p<0.01 vs. vehicle group, t-test on log-transformed
data (hematology) or t-test or Wilcoxon test (clinical chemistry),
as appropriate.
Table V. Histopathology findings in NSGmice after three intrave-
nous injections of 2£ 106 ABCB5+ MSCs/animal or vehicle with-
out cells on day 1, 15 and 29.
Number of affected/
examined animals
Organ/tissue and findings Vehicle 2£ 106 MSCs/animal
Males
Epididymides
Sperm reduced, luminal,
moderate
1/10 0/9
Spermatocele, moderate 0/10 1/9
Kidneys
Basophilia, tubular,
minimal
0/10 1/9
Liver
Necrosis, hepatocellular,
focal, minimal
0/10 1/9
Spleen
Metaplasia, osseous,
slight
1/10 0/9
Testes
Atrophy, minimal 3/10 3/9
Females
Kidneys
Dilatation, tubular,
minimal
2/10 0/10
Liver
Necrosis, hepatocellular,
focal, minimal
0/10 1/10
Lungs and bronchi
Thrombus, minimal 1/10 2/10
Macrophage aggregation,
alveolar, minimal
1/10 0/10
Pancreas
Vacuolation, acinar cells,
minimal
0/10 1/10
Spleen
Metaplasia, osseous,
slight
0/10 1/10
Uterus
Dilatation, glandular,
cystic, minimal
6/10 7/10
Animals were followed up for 13 weeks.
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These reactions were judged as normal consequence
of injection of a volume into muscular tissue. Degen-
erative and inflammatory processes were quantified
as summary score for local cellular and tissue
response according to ISO 10993-6:2007 [13],
including the criteria polymorphonuclear cells, lym-
phocytes, plasma cells, macrophages, giant cells,
myofiber degeneration, myofiber regeneration,
necrosis, neovascularization, fibrosis and fatty infil-
trate. MSC-treated animals exhibited a minor
increase in the mean summary score for local cellular
and tissue response (4.6 compared with 3.7 for vehi-
cle-treated animals). This increase paralleled with
the presence of administered MSCs as detected by
vimentin and b2-microglobulin mesenchymal cell
staining, which formed small strands or foci of mes-
enchymal cells. These were associated with minimal
fibrotic reactions observed in the corresponding
H&E-stained sections (Figure 3, right), which
demarcated the cell groups from the surrounding tis-
sues. Local intolerance of the applied product was
not deduced from these findings.
Twenty-eight-day local tolerance of intramuscularly
injected ABCB5+ MSCs and of the vehicle
To investigate the effects of both, ABCB5+ MSCs
and the vehicle (HRG), on local myofiber degenera-
tion and regeneration over a somewhat longer period,
male NOG mice were intramuscularly injected with
either 5£ 106 ABCB5+MSCs/animal in 200 mL vehi-
cle (n = 8), 200 mL vehicle without cells (n = 8) or 200
mL PBS (to detect or rule out possible effects of the
HRG vehicle, n = 8). Mice were followed up for
28 days, during which nearly all animals were incon-
spicuous. Only one PBS-injected animal died 3 days
upon application for an unknown reason. The fact
that this mouse was considerably more strongly
Figure 2. Histological evaluation of the persistence of human cells in the lungs of NSG mice treated with three bi-weekly intravenous injec-
tions of 2£ 106 ABCB5+ MSCs/mouse. Mice were sacrificed at 13 weeks after the first MSC injection. Tissues were stained with anti-
mitochondrial antibody (AMA) (brown) as a marker of human-origin cells. (Left) Skin at the injection site of a mice injected subcutaneously
with 1.08£ 106 HeLa cells served as positive control. (Middle and Right) Representative microphotographs of lung sections of MSC-treated
mice in which AMA staining was exceptionally rare. Scale bars: 50 mm.
Figure 3. Histopathological evaluation of local reactions in thigh muscle tissue of NOG mice to intramuscular injection of 200 mL HRG
solution without (left) and with (right) 5£ 106 ABCB5+ MSCs/mouse, split over four injection sites. (Left) Mice were sacrificed at 7 days
after cell injection. Representative microphotograph of a thigh muscle section of a control animal, treated with vehicle only, showing slight
focal myofiber degeneration (arrows) and regenerative myoblasts (arrowheads). (Right) Representative microphotograph of a thigh muscle
section of an MSC-treated mouse, showing focal accumulation of mesenchymal cells with minimal fibrotic aspect. H&E staining; magnifica-
tion 20£ (left), 40£ (right); scale bars: 20 mm.
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affected by the anesthesia applied for injection than
were the other animals may point to an unrecognized
pre-existing condition that eventually had led to its
premature death. Macroscopic appearance of the
thigh muscles during necropsy was inconspicuous.
Histopathological evaluation revealed no treatment-
related irritation in any of the tested samples. Only
mild myofiber degeneration was detected in one
MSC- and in one PBS-treated animal. These reac-
tions were considered incidental and judged as a nor-
mal consequence of injection of a volume into
muscular tissue.
Discussion
In the nonclinical in vivo studies presented here, we
investigated and demonstrate the safety and tolerabil-
ity ABCB5+ MSCs in view of a potential therapeutic
in-human use. Basically, the testing strategy followed
the recommendations of the European Medicines
Agency [14], considering the specific nature of the
product and its intended clinical use. Accordingly, it
was crucial to demonstrate that the applied cells do
not show unwanted homing or even proliferation.
Strong attention was paid to possible tumor formation
potential and toxicological effects during short and
longer (up to 4 months) periods of time. All these
aspects were addressed in severely immunocompro-
mised mice, to prevent rejection of the applied cells
by the xenogeneic host’s immune system. This should
have provided the greatest possible ability to detect
any ectopic tissue- or tumor-forming potential of the
administered cells. To capture any impact of possible
cellular alterations that may occur during the cell
expansion and ATMP production process, the final
GMP-produced ATMP as intended for use in clinical
trials was tested in all studies.
Studying the distribution and persistence behavior
after local (subcutaneous) injection, we showed that
the applied ABCB5+ MSCs were confined to the
injection site and virtually did not migrate to other tis-
sues and organs, including the reproductive organs.
Cell concentrations in the injection-site tissues
decreased over time and had reached non-detectable
levels in all but one sample at 3 months. This is in line
with earlier results on placenta-derived MSCs [15],
showing that locally administered MSCs do not per-
sist for longer periods but are eradicated even from
severely immunocompromised hosts.
Biodistribution and possible persistence and pro-
liferation potential of ABCB5+ MSCs were also inves-
tigated after systemic (intravenous) application of the
cell product. The first barrier for intravenously admin-
istered cells is the capillary bed of the lung, and
because culture-expanded MSCs are relatively large
cells, obstructive events such as intravascular emboli
formation may seem likely during lung passage [16].
Indeed, “first-pass” accumulation of intravenously
delivered MSCs in the lungs has been repeatedly
described [1720]. The risk that such mechanical
cell entrapment causes pulmonal embolus formation
grows with increasing cell concentrations, which may
result in insufficient dilution of the cells in the circu-
lating blood [17]. Thus, it was crucial to test the same
cell concentration as that we intend to use in clinical
trial (i.e., 1£ 107 MSCs/mL, corresponding to
2£ 106 MSCs/mouse, given the maximal injection
volume of 200 mL recommended for intravenous
injections to mice [21]). This cell load was well toler-
ated without clinical signs or mortality. Human-origin
cells were predominantly recorded in the injection-
site tissues (skin and skeletal muscle) and in the lungs,
as expected. The observed kinetics over time suggests
a certain degree of persistence of the cells in these tis-
sues (Figure 1). However, the cells did not appear to
readily traffic, home or engraft on tissues beyond the
immediate area of the dose site and the lung as “first-
pass” organ.
For evaluation of these findings in view of the
expectable safety of ABCB5+ MSCs given intrave-
nously to humans, it should be considered that the
data were obtained in severely immunocompromised
(NSG) mice. Culture-expanded MSCs show an inef-
ficient homing potential, which is apparently due to a
deficit or even lack of relevant cell adhesion and che-
mokine receptors responsible for coordinated extrava-
sation and tissue-specific homing [20,22]. In
immunocompetent (C57BL/6) mice intravenously
injected with human bone marrow-derived MSCs,
qPCR revealed a rapid loss of traceable human DNA
within the first 24 h after injection. At that time point,
only <0.1% of the initially injected cells were detect-
able in the lungs (maximum: 52.5% at 5 min), and
human cells were undetectable in the liver (maximum:
0.05% at 2 h) [23]. Immunodeficiency, as was the
case in the present study, seems to have a favoring
effect on persistence of exogenous cells, which, how-
ever, would not be given in non-immunosuppressed
human patients.
Another major concern regarding the safety of stem
cell therapies is a potential tumorigenic risk [24]: first,
stem cells present some characteristics that are also
seen in cancer cells, including long life span, self-
renewal, high proliferation rate and relative resistance
to the host’s immune defense mechanisms such as apo-
ptosis [6]. Second, MSCs could aggravate (potentially
undiagnosed) pre-existing neoplastic diseases in the
host by promoting tumor growth and metastasis
through various mechanisms, including the MSCs’
immunomodulatory properties, by which they could
suppress the host’s anti-tumor response [25,26], and
their pro-angiogenic capacities, by which they may
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facilitate tumor growth and metastasis [27]. Third,
neoplastic transformation of MSCs may result from an
accumulation of genetic and/or epigenetic changes,
which may occur during the process of in vitro stem
cell expansion, isolation and ATMPmanufacture [24].
Transformation has been observed in long-term cul-
tures of bone marrowderived MSCs [2830],
although other investigators have described such events
as very rare or even failed to observe any at all [3133].
Together, a thorough tumor risk assessment after local
and systemic application is essential for biosafety evalu-
ation of MSC-based therapies, even if MSC-originat-
ing tumors have never been diagnosed in several
hundreds of patients treated with MSCs [7,8,34,35].
The tumorigenicity studies were combined with
the studies for toxicity assessment, which allowed for
keeping animal numbers as low as possible and
reduce potential interstudy variance. Doing so
seemed reasonable given that toxicity studies on cell-
based medicinal products require longer observation
periods than conventional single-dose toxicity stud-
ies because the applied cells may be effective for lon-
ger times than conventional medicinal products,
either because they may not immediately be rejected
or by affecting resident cells eliciting effects that con-
tinue even after the applied cells are no longer pres-
ent in the tissue [36].
In the subcutaneous study, the predominant find-
ings were systemic lymphoblastic neoplasms seen
throughout all groups treated with ABCB5+ MSCs or
vehicle, with incidences ranging between 5% in the
medium-dose MSC group and 17% in the vehicle
group. These tumors were, however, clearly judged
not related to the application of ABCB5+ MSCs for
three reasons: first, these tumors were observed in
both, MSC- and vehicle-treated groups. Second, the
obvious hematopoietic/lymphatic (and thus non-mes-
enchymal) origin of the tumors together with the
absence of human DNA sequences in the affected
organs as confirmed by qPCR ruled out any involve-
ment of the applied human ABCB5+ MSCs. Third,
spontaneously developing lymphomas are known to
be a frequent occurrence in NOD-scid mice [11],
which were used in this study. In contrast, in the intra-
venous study, which instead used NSG mice, which
exhibit only a very low spontaneous lymphoma inci-
dence [37], neither in the vehicle- nor in the MSC-
treated group any signs of gross tumor development,
ectopic tissue formation or micrometastases were
observed. In the lungs of the MSC-treated animals, a
small amount of the administered ABCB5+ MSCs
persisted during the observation period. Combined
AMA and Ki67 staining demonstrated, however, that
these cells were not proliferating.
The question may arise whether a 12-week (sub-
cutaneous) or 13-week (intravenous study) follow-
up is actually sufficient for ruling out a tumorigenic
potential of the MSCs, considering that in one skin
sample in the subcutaneous biodistribution study
human cells were detected at 3 months (which could
have persisted even longer if the animal was not sac-
rificed). However, it needs to be considered that the
data were obtained in severely immunocompromised
mice to prevent degradation of rejection of the
MSCs by the host’s immune system and extend cell
survival and persistence in the host for as long as pos-
sible. Thus, the level of cell survival observed in our
studies is far above of what is expected in an immu-
nocompetent organism. In immunocompetent
(C57BL/6) mice intravenously injected with human
bone marrowderived MSCs, qPCR revealed a
rapid loss of traceable human DNA already within
the first 24 h. At that time point, for example, only
<0.1% of the initially injected cells were detectable
in the lungs (maximum: 52.5% at 5 min) [23].
As with the tumorigenicity parts of the studies,
their toxicity parts did not reveal any significant effect
of ABCB5+MSCs in either dose tested on the param-
eters investigated. In general, either no significant dif-
ferences between vehicle- and MSC-treated animals
were observed, or the observed findings were judged
unrelated to the treatment with ABCB5+ MSCs,
based on their incidence and distribution.
Taken together, these studies demonstrate that
repeated (three monthly) subcutaneous injections of
human skinderived ABCB5+ MSCs at doses rang-
ing from 1£ 105 to 1£ 107 cells/mouse and repeated
(three biweekly) intravenous injections of human
ABCB5+ MSCs at a dose of 2£ 106 cells/mouse,
respectively, were non-tumorigenic and nontoxic,
with 1£ 107 ABCB5+ MSCs/mouse (for subcutane-
ous application) and 2£ 106 cells/mouse (for intra-
venous application), respectively, being considered
the “no observed adverse effect level” (NOAEL). As
these doses represent the highest doses tested in our
studies, the actual NOAEL might be even higher.
Although we cannot state with certainty that our
studies exactly duplicated the biodistribution condi-
tion in humans, the use of immunocompromised
mice can be expected to have provided the greatest
possible cell survival. This allows for reasonable
translation of our animal-derived data to the alloge-
neic but immunocompetent human setting.
An issue that could not be studied NSG mice,
which lack mature T-, B- and natural killercell
activity, is the potential development of antibodies
against foreign cell antigens. On the other hand,
studies of human MSCs in immunocompetent mice
would reflect the xenogeneic situation and thus pro-
vide only limited informative value in view of human
(i.e., allogeneic) use. Given the multifaceted immu-
nosuppressive properties of ABCB5+ MSCs [35],
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the generally low immunogenicity of MSCs [2,38]
and the observation that occasional anti-donor anti-
body formation following repeated intravenous MSC
injections was associated with neither clinical conse-
quences nor with loss of therapeutic efficacy of the
applied cells [39,40], we do not expect any signifi-
cant safety concerns.
Finally, to facilitate intramuscular application
settings, two studies were specifically designed to
investigate short-term (7 days) and longer-term (29
days) intramuscular local tolerance. The latter study
involved an additional group that was treated with
PBS to detect any potential local side effect of the
HRG vehicle. No clinical and macroscopic abnor-
malities were observed in these studies. Microscopic
reactions were for the most part judged as a normal
consequence of injection of a volume into muscular
tissue. Local intolerance, emanating from either the
MSCs or from the vehicle, could not be deduced
from the findings of these studies. One may speculate
that the immunocompromised state of the animals
may have prevented or masked potential local tissue
reactions that would otherwise occur. Although such
a contribution cannot be definitively ruled out, it
may be emphasized that good intramuscular tolera-
bility of MSCs of various sources has also been
observed in the immunocompetent organism, as was
demonstrated, for example, with intramuscular
injections of human bone marrowderived MSCs to
C57BL/6 mice [41] or of adipose tissuederived
MSCs to humans [42].
In conclusion, the present study program covered
the specific aspects to be addressed in preclinical
safety studies for somatic cell therapy medicinal
products [43], including the evaluation of distribu-
tion and engrafting after administration, ectopic
engraftment and oncogenic transformation. The set
of tests and pattern of analysis may be generally
applicable to preclinical safety and tolerability evalu-
ation of MSC-based medicinal products. Our data
demonstrate the preclinical safety and tolerability of
a novel ATMP based on human skinderived
ABCB5+ MSCs that may represent a significant con-
tribution toward the unmet medical needs of various
degenerative and inflammatory conditions.
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